补髓生血颗粒为主治疗骨髓增生异常综合征之难治性贫血的临床观察
|
摘要
本论文在对骨髓增生异常综合征(简称MDS)近年来的治疗和研究进行综述后，对40例MDS-RA患者进行了临床观察研究。以补髓生血颗粒加全反式维甲酸(ATRA)为治疗约物，与ATRA作对照，通过临床疗效总结探讨补髓生血颗粒治疗MDS-RA的机理。
在研究后我们发现，治疗组治疗MDS-RA的有效率为76.19％，优于对照组疗效(42.11％)，两者比较差异显著(P＜0.05)。
治疗组贫血及出血症状明媪改善，二者治疗前后比较差异均显著(P＜0.05)，其改善程度优于对照组。
治疗后，治疗组外周血象明显改善，血红蛋白、白细胞和血小板治疗前后比较差异显著(P＜0.01)，治疗组外周血象改善程度优于对照组。
治疗后，治疗组外周血及骨髓中的幼稚细胞数较疗前均明显降低(P＜0.01)，且其降低程度均优于对照组。
治疗后，治疗组外剧血及骨髓中的病态造血现象较疗前均有改善，治疗前后比较差异显著(P＜0.01)。且其改善程度均优于对照组。
以上结果显示，治疗组可以有效改善MDS-RA的贫血、出血症状及外周血象，降低外周血及骨髓中幼稚细胞数和病态造血现象，其疗效优于对照组，提示补髓生血颗粒是治疗MDS-RA的有效方剂。
This thesis paper summarizes the treatment and study on Myelodysplastic Syndrome (abbreviated as MDS) in recent years, then makes a clinical observation and study on 40 Refractory Anemia (abbreviated as RA) patients, using marrow- supplementing and blood-engendering granule plus all-trans retinoic acid as therapeutic medicine, and summarizes therapeutic principle of marrow- supplementing and blood-engendering granule to MDS-RA.
After study we find that total MDS-RA therapeutic effect rate in treatment group is 76.19 %, which is superior to that of the controlled group (42.11%), there is significant differences between two groups (P<0.05).
After treatment, there is significant improvement of anemia and hemorrhage symptom in treatment group, and compared with that before treatment, the differences is significant (P<0.05), and the improvement degree is superior to that in the controlled group (P<0.05).
After treatment, there is significant improvement of peripheral blood in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group.
After treatment, there is significant discrease of immature cells in peripheral blood and bone marrow in treatment grpup, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to tha.t in the controlled group.
After treatment, there is significant improvement of morbid
generating blood phenomenon in both peripheral blood and bone marrow in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group (P<0.05).
The result above shows marrow-supplementing and blood-engendering granule can effectively improve anemia and hemorrhage symptom and peripheral blood, decrease immature cells in peripheral blood and bone marrow, the degree of which is superior to that in controlled group, and shows marrow-supplementing and blood-engendering granule is an effective prescription for treating MDS-RA.
在研究后我们发现，治疗组治疗MDS-RA的有效率为76.19％，优于对照组疗效(42.11％)，两者比较差异显著(P＜0.05)。
治疗组贫血及出血症状明媪改善，二者治疗前后比较差异均显著(P＜0.05)，其改善程度优于对照组。
治疗后，治疗组外周血象明显改善，血红蛋白、白细胞和血小板治疗前后比较差异显著(P＜0.01)，治疗组外周血象改善程度优于对照组。
治疗后，治疗组外周血及骨髓中的幼稚细胞数较疗前均明显降低(P＜0.01)，且其降低程度均优于对照组。
治疗后，治疗组外剧血及骨髓中的病态造血现象较疗前均有改善，治疗前后比较差异显著(P＜0.01)。且其改善程度均优于对照组。
以上结果显示，治疗组可以有效改善MDS-RA的贫血、出血症状及外周血象，降低外周血及骨髓中幼稚细胞数和病态造血现象，其疗效优于对照组，提示补髓生血颗粒是治疗MDS-RA的有效方剂。
This thesis paper summarizes the treatment and study on Myelodysplastic Syndrome (abbreviated as MDS) in recent years, then makes a clinical observation and study on 40 Refractory Anemia (abbreviated as RA) patients, using marrow- supplementing and blood-engendering granule plus all-trans retinoic acid as therapeutic medicine, and summarizes therapeutic principle of marrow- supplementing and blood-engendering granule to MDS-RA.
After study we find that total MDS-RA therapeutic effect rate in treatment group is 76.19 %, which is superior to that of the controlled group (42.11%), there is significant differences between two groups (P<0.05).
After treatment, there is significant improvement of anemia and hemorrhage symptom in treatment group, and compared with that before treatment, the differences is significant (P<0.05), and the improvement degree is superior to that in the controlled group (P<0.05).
After treatment, there is significant improvement of peripheral blood in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group.
After treatment, there is significant discrease of immature cells in peripheral blood and bone marrow in treatment grpup, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to tha.t in the controlled group.
After treatment, there is significant improvement of morbid
generating blood phenomenon in both peripheral blood and bone marrow in treatment group, and compared with that before treatment, the differences is significant (P<0.01), and the improvement degree is superior to that in the controlled group (P<0.05).
The result above shows marrow-supplementing and blood-engendering granule can effectively improve anemia and hemorrhage symptom and peripheral blood, decrease immature cells in peripheral blood and bone marrow, the degree of which is superior to that in controlled group, and shows marrow-supplementing and blood-engendering granule is an effective prescription for treating MDS-RA.
引文
1．孙伟正，刘丽波，孙凤，等。《中医血液病学》，北京：中国医药科技出版社，2000：132
2．梁冰，李达，王会明，等。《专科专病名医临证经验丛书血液病》，人民卫生出版社，2002，1：220～237
3．陈信义。骨髓增生异常综合征中西医结合治疗思路。中国中西医结合杂志，2003，23(4)：252
4．马明。祖国医学对骨髓增生异常综合征的认识。中医药信息，1992，(6)：10
5．杨养贤，王锐，周淑意。中西医结合治疗MDS19例分析。西安医科大学学报，1995，16(1)：94
6．王质彬。骨髓增生异常综合征的中西医结合治疗。中日友好医院学报，2003，17(1)：56
7．叶欧江，赵巍，李晓琳。中西医结合治疗骨髓增生异常综合征(RAEB，RAEB-t)48例报告．实用肿瘤杂志，2001年，16(3)：199
8．胡凯文，孙颗立，乐兆生，等。益气养阴活血法治疗骨髓增生异常综合征。北京中医药大学学报，1994，17(2)：39
9．许毅，周永明，黄振翘，等。健脾补肾活血法为主治疗骨髓增生异常综合征的临床观察。上海中医药杂志，2001(7)：11
10．陈瑜，汤金土，马珂。活血化瘀为主治疗难治性贫血28例观察。浙江中医杂志，1998，8：345
11．王展翔，麻柔，邓金福，等。扶正祛邪丹治疗骨髓增生异常综合征的临床及实验研究。中国中西医结合杂志，1999，11(11)，664～666
12．张庆祯，崔立献。中西医结合治疗骨髓增生异常综合征24例。中国中西医结合杂志，1996，6：362
13．孙伟正，曲佳丽。中医辨证．施治合并康力龙治疗骨髓增生异常综合征15例疗效观察，中医药信息，1991，(5)：20
14．王继亮。中西医结合治疗骨髓增生异常综合征。实用中西医结合杂志，1995，
(10)：585
15．郭陪京，李国章，刘品莉，等。中药益髓康为主治疗骨髓增生异常综合征临床观察．中国中西医结合杂志，1995，15(2)：74～76
16．刘岐焕，程范军。益血康为主治疗骨髓增生异常综合征的临床研究。湖北中医杂志，2001，23(4)：7
17．徐才刚，吴俣，朱焕玲，等。复方皂矾丸治疗骨髓增生异常综合征的临床对照研究。华西医学，2003：18(2)：193～194
18．柏春梅，刘润侠，刘捷。滋肾益髓汤治疗难治性贫血26例。陕西中医，1997，18(5)：193
19．陈信义，肖萍，胡凯文，等。益髓灵颗粒剂改善骨髓巨核系病态造血的临床研究。北京中医药大学学报，1998，21(1)：44
20．谢志正，王辉。骨髓增生异常综合征治验。陕西中医，1992，(2)：75
21．甘欣锦，李晓惠，张永健。难治性贫血中医辨证验案一例。实用中西医结合杂志，1992，5(12)：753
22．王秀婷，贺海涛。中西医结合治疗骨髓增生异常综合征。中国中西医结合杂志，1993，(7)：410
23．陈信义，李冬云。中医药防治骨髓增生异常综合征的研究现状与展望。北京中医药大学学报，1996，19(2)：10～11
24．李学军，周莲云。补髓生血冲剂对骨髓增生异常综合征骨髓造血祖细胞体外增殖的影响。福建中医药，2001年，32(4)：38～39
25．高学熙，王信琪，马建军。雄黄治疗骨髓增生异常综合征14例。临床内科杂志，1998，15(3)：125
26．佟红艳，林茂芳。三氧化二砷诱导入骨髓增生异常综合征细胞MUTZ-1细胞p151NK4B基因表达的研究。中华血液学杂志，2002，23(12)：638-641
27．陈信义，韦云，苏伟，等。流式细胞仪分析益髓灵对MDS患者T细胞亚群的影响。中国中医基础医学杂志，1995，(3)：22
28．陈信义，韦云，苏伟，等。益髓灵对MDS患者血淋巴细胞周期影响的初步研究，中国中医基础医学杂志，1995，(1)：47
29．张洪均。益骨灵对白血病巨核细胞系HI-Meg增殖与分化影响的研究。中国组织化学与细胞化学杂志，1996，5(4)：43
30．张洪钧，陈信义，宋玉华，等。YSL对白血病巨核细胞系HI-Meg基因表达影响的初步研究。中国中医基础医学杂志，1996，2(1)：43
31．陈信义，张洪钧。益髓灵及其拆方对巨核系病态造血细胞影响的研究。北京中医药大学学报，1995，18(5)：34
32．黄韬，黄振翘，周永明，等。骨髓增生异常综合征骨髓细胞对不同中药治疗的反应性研究。第三届中国中医血液病学术论文集，上海：上海中医药大学，1999．11
33. Hoppc RT. Secondary leukemia and myelodysplastic syndromes after treatment for Hodgkin's disease. Leuk Res 1992, 6(Suppl): 135
34. Rosenbloom B, Schreck R, Koeffler HP et al. Therapy-related myelodysplastic syndromes. Hematol/oncol Clin Nor Am, 1992, 6(3): 707
35. Levine EG, Blocmfild CD. Leukemia and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol, 1992; 19:47
36. Yardly-Joners A, Anderson D, Prker DV. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. Br J Ind Med, 1991, 48:437
37. Brandt L. Exposure to organic solvents and risk of hematological maligancies. Leuk Res, 1992,6(1): 67
38. Nisse C, Lorthois C, Dorp V et al. Exposure to occupational and environmental factors in myelodysplastic Syndromes. Preliminary results of a case-control study. Leuk, 1995, 9:693
39. West RR, Stafford DA, Farrow A et al. Occupational and environmental exposures and.myelodysplasia:A Case-control study. Leuk Res, 1995,19:127
40. Mele A, Szklo M, Visani G et al. Hair dye used and other risk factors for leukemia and preleukemia. A case-control study. Am J Epidemioi, 1994,139:609
41．黄友章，杨平地，汪声恒，等。骨髓增生异常综合征与再生障碍性贫血相互转化观察1例报告。海军总医院学报，2001，14(1)：63～64
42．王冬梅，马茉莉。结核后骨髓增生异常综合征5例临床分析。白血病·淋巴瘤，2001，10(4)：240～241
43. Levine EG, Blocmfild CD. Leukemia and myelodysplastic syndromes secondary to drug, radiation and envionmental exposure. Semin Oncol, 1992 (19): 47
44．胡喜梅，薛文韬，高晖，等。骨髓增生异常骨髓细胞免疫表型的探讨．临床血液学杂志，1998，11(3)：101～104
45．谢彦晖，林果为，竹髓增生异常综合征血细胞酶及同功酶改变的研究进展．中华血液学杂志，1993，14(8)：440～442
46. Sawada K, Sato N, Notoy A, et al. Proliferation and differentiation of myelodysplastic CD_(34)~+cells: phenotypic subpopulations of narrow CD_(34)~+cells. Blood, 1995, 85(1): 194-202
47. Takahiro O, M asaya O, Tohru I, et al. Myclodysplastic syndrome with B cell eionality in a patient five years after renal transplantation. Inte J Hematol, 1998, 68(1): 61～65
48．徐开林，王立，郝玉书，等。骨髓增生异常综合征Evil T和MDS-Evil基因表达的研究．中华血液学杂志，1998，19(6)：315～319
49. Hellstrom LE, Kanter LL, Ost A. Morphological change and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoitin. Leuk Res, 1997, 21(5): 415～425
50. Deliliers gl, Soligo D, OrianiA et al. Increased expression of bcl-2 protein in the bone marrow biopsies of patients with primary MDS. Leuk Res, 1994, 18(suppll):5
51. Davis RE, Greenberg P1. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes (MDS): immuostaining of bone marrow (BM) biopsies. Blood, 1994, 84(suppll): 314a
52．操洲虹，李蓉生，李琦。细胞因子对骨髓增生异常综合征造血细胞凋亡的影响及临床意义。中华血液学杂志，1998，18(1)：27～30
53．邓家栋，杨崇礼，杨天楹，等。临床血液病学。上海：上海科技出版社。753～765
54. Bennet JM et al. Proposals for the classification of myeiodysplastic syndrome. Brit J Haematol, 1982,51:89
55．肖志坚，郝玉书。骨髓增生异常综合征的诊断和治疗。中华血液学杂志。2004，25(1)：61
56. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase Ⅱ study of a combination of fludarabine phosphate, cytarabine and granulocyte
colony-stimulating factor in relapsed and refractory acute myeloid ieukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol, 2001, 112:127-137
57. Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome. Cancer, 2001, 92:1999-2015
58. Okamoto T, Kanamaru A, Shimazaki C, et al. Combination chemotherapy with risk factor-adjusled dose attenuation for high-risk myclodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis. IntJ He matol, 2000, 72:200-205
59. Saito K, Nakamura Y, yoyagi M, et al. Low dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J He matol, 2000, 71:238-244
60. Hast R, Walivik J, Folin A, et al. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res, 2001, 25:13-18
61. Molldrem J J, Jiang Y X, M avroudis D, et al. Hematological response of patients with myelodysplastic syndrome (MDS) to antithymocyte globuline (ATG) treatment is assoicated with a loss of CD_8~+T-cell mediated CFU-GM inhibition. Blood, 1997, 90(Suppl): 85a
62. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic, myelodysplastic syndrome patients and certain refractory anemia without hypoplastic bone marrow. Brit J Hematol, 1998, 100:304
63. I Raza A, Meyer P, Dutt D, et al . Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 2001, 98:958-965
64. Grossl A, Fabbri A, Santini V, et al. Amifostine in the treatment of low risk myelodysplastic syndromes. Haematologica, 2000, 85:367～371
65. Raza A,Qawi H, Lisak L, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifyiline, and ciprofioxacin with or without dexamethasone. Blood, 2000, 95:1580～1587
66. Tefferi A, Elliott MA, Steensma DP, et al. Amifosline nlone and in combination with erythropoietin fox the treatment of favorable myelodysplastic syndrome. Leuk Res, 2001, 25:183～185
67. Zorat F, Shetty V, Dull D, ea al. The clinical and biological effects of thalidomide with mylodysplastic syndromes. Br J Ilaematol, 2001, 115:881～894
68. Cortelezzi A, Cattaneo C, Sarina B, et al. Efficacy of N-acetylcysteine and all-trans retinoic acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromes. Leuk Res, 2000, 24:129～13
69. Venditti A, Tamburini A, Buccisano F, et al. Aphase-Ⅱ trial of all-trans retinoic acid and low dose cytosine arabinoside for the treatment of high risk myelodysplastic syndromes. Ann Hematol, 2000, 79:138～142
70. Stasi R, Brunetti M, Terzoli E, et al. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood, 2002, 99:1578～1584
71. Hofmann WK, Kell WJ, Fenaux P, et al. Oral 9-cis retinoic aeid(Alit-retinoin) in the treatment of myelodysplastic syndromes:results from a pilot study Leukemia, 2000, 14:1583～1588
72. M illibovsky L, Diez A, Perez-Vila E, et al. Vitamin D treatment in m yelodysplastic syndromes. Brit J Hematol, 1009,199:516
73. KizakiM, Takayam a N, Kaw asi Y, et a I.Development of acute erythremia from myelodysplastic syndrome after treatment with 1, 25-dihdroxy-vitamin D3 [J]. Amer J Hem atol, 2001, 67:215
74. Teofili L, Martini M,di Mario A, et al. Expression of p15 (INK4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood, 2001, 98:495-497
75. Tien HP, Tang JH, Tsay W, et al. Methylation of the p15 (INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease
progression and is highly associated with leukaemic transformation. Br J Haematol, 2001, 112:148-154
76. Lubbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndromc follwing low dosc trcatment with the DNA methylation inhibitor 5-aza-2-deoxycytidine. Br J Hacmatol, 2001, 114:349-357
77. Takam i A, Asakura H, M akao S Menatetranone, a vilamin K2 analog,ameliorate cytopcnia in patients with refractory anemia of myclodysplastisyndrome[JJAnn Hem atol, 2002, 81:16
78．张琳，杨青，郭建民，等。二氧化二砷治疗高危骨髓增生异常综合征22例．[J]河南医科大学学报，2001，36：772
79．丛秀丽，马永贞，钱林生。临床血液学杂志，2003，16(4)：180～182
80．张之南，沈悌，丁训杰，等。《血液病诊断及疗效标准》，北京：科技出版社，1998：260
81．张洪钧，孙颖立，陈信义，等。中医药治疗骨髓增生异常综合征．北京中医学院学报，1993，16(3)：39～41
82．毕临林。中药治疗骨髓增生异常综合征87例。河南中医。2001，21(2)：42
83．唐由君。中药为主治疗骨髓增生异常综合征22例的观察。浙江中医杂志，1992，(5)：204
84．唐由军，邬佐莉。骨髓增生异常综合征治经验。浙江中医杂志，1995，2：53～54
85. Bogdanovic AD, Jankovic GM, coiovic MD.Aoptosis in bone marrow of myelodysplastic syndrome patients. Blood, 1996, 87:3064
86. Heilstrom-Lindberg E, Kanter Lewensohn L,Ost A. Morphological change and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoitin. Leuk Res ,1997, 21:415～425
87. Raza A, Mundle S,Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes:excessive apoptosis and the role of cytokines. Int J He matol, 1996, 63:265-278
88. Kliche KO, Andxeeff M. Hyperapoptosis as pathophysiologic basis of myeiodysplastic syndromes (MDS). Blood, 1996, 88:639
89. Bouscary D, Ves JD, Guesnu M, et al. Fas/Apo-1(CD_(95))expression and apoptosis in
patients with myelodysplastic syndromes Leukemia, 1997, 11:839～845
90. Tsoplou P, Kourakli-Symeonidis A, Thepoulou E, et al.Apoptosis in patients with myelodysplastic syndrome (MDS): differential involvement of marrow cell in early versus advanced cases and correlation with the expression of apoptosis related genes Blood, 1997, 90: 203a
91. Mufti GJ. Ineffective haemapoiesis and apoptosis in myelodysplastic syndromes Br J Haematol, 1998, 101:220～230
92. Rajapaksa R, Ginzlon N, Rote LS, et al Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 1996, 88:4275～4287
2．梁冰，李达，王会明，等。《专科专病名医临证经验丛书血液病》，人民卫生出版社，2002，1：220～237
3．陈信义。骨髓增生异常综合征中西医结合治疗思路。中国中西医结合杂志，2003，23(4)：252
4．马明。祖国医学对骨髓增生异常综合征的认识。中医药信息，1992，(6)：10
5．杨养贤，王锐，周淑意。中西医结合治疗MDS19例分析。西安医科大学学报，1995，16(1)：94
6．王质彬。骨髓增生异常综合征的中西医结合治疗。中日友好医院学报，2003，17(1)：56
7．叶欧江，赵巍，李晓琳。中西医结合治疗骨髓增生异常综合征(RAEB，RAEB-t)48例报告．实用肿瘤杂志，2001年，16(3)：199
8．胡凯文，孙颗立，乐兆生，等。益气养阴活血法治疗骨髓增生异常综合征。北京中医药大学学报，1994，17(2)：39
9．许毅，周永明，黄振翘，等。健脾补肾活血法为主治疗骨髓增生异常综合征的临床观察。上海中医药杂志，2001(7)：11
10．陈瑜，汤金土，马珂。活血化瘀为主治疗难治性贫血28例观察。浙江中医杂志，1998，8：345
11．王展翔，麻柔，邓金福，等。扶正祛邪丹治疗骨髓增生异常综合征的临床及实验研究。中国中西医结合杂志，1999，11(11)，664～666
12．张庆祯，崔立献。中西医结合治疗骨髓增生异常综合征24例。中国中西医结合杂志，1996，6：362
13．孙伟正，曲佳丽。中医辨证．施治合并康力龙治疗骨髓增生异常综合征15例疗效观察，中医药信息，1991，(5)：20
14．王继亮。中西医结合治疗骨髓增生异常综合征。实用中西医结合杂志，1995，
(10)：585
15．郭陪京，李国章，刘品莉，等。中药益髓康为主治疗骨髓增生异常综合征临床观察．中国中西医结合杂志，1995，15(2)：74～76
16．刘岐焕，程范军。益血康为主治疗骨髓增生异常综合征的临床研究。湖北中医杂志，2001，23(4)：7
17．徐才刚，吴俣，朱焕玲，等。复方皂矾丸治疗骨髓增生异常综合征的临床对照研究。华西医学，2003：18(2)：193～194
18．柏春梅，刘润侠，刘捷。滋肾益髓汤治疗难治性贫血26例。陕西中医，1997，18(5)：193
19．陈信义，肖萍，胡凯文，等。益髓灵颗粒剂改善骨髓巨核系病态造血的临床研究。北京中医药大学学报，1998，21(1)：44
20．谢志正，王辉。骨髓增生异常综合征治验。陕西中医，1992，(2)：75
21．甘欣锦，李晓惠，张永健。难治性贫血中医辨证验案一例。实用中西医结合杂志，1992，5(12)：753
22．王秀婷，贺海涛。中西医结合治疗骨髓增生异常综合征。中国中西医结合杂志，1993，(7)：410
23．陈信义，李冬云。中医药防治骨髓增生异常综合征的研究现状与展望。北京中医药大学学报，1996，19(2)：10～11
24．李学军，周莲云。补髓生血冲剂对骨髓增生异常综合征骨髓造血祖细胞体外增殖的影响。福建中医药，2001年，32(4)：38～39
25．高学熙，王信琪，马建军。雄黄治疗骨髓增生异常综合征14例。临床内科杂志，1998，15(3)：125
26．佟红艳，林茂芳。三氧化二砷诱导入骨髓增生异常综合征细胞MUTZ-1细胞p151NK4B基因表达的研究。中华血液学杂志，2002，23(12)：638-641
27．陈信义，韦云，苏伟，等。流式细胞仪分析益髓灵对MDS患者T细胞亚群的影响。中国中医基础医学杂志，1995，(3)：22
28．陈信义，韦云，苏伟，等。益髓灵对MDS患者血淋巴细胞周期影响的初步研究，中国中医基础医学杂志，1995，(1)：47
29．张洪均。益骨灵对白血病巨核细胞系HI-Meg增殖与分化影响的研究。中国组织化学与细胞化学杂志，1996，5(4)：43
30．张洪钧，陈信义，宋玉华，等。YSL对白血病巨核细胞系HI-Meg基因表达影响的初步研究。中国中医基础医学杂志，1996，2(1)：43
31．陈信义，张洪钧。益髓灵及其拆方对巨核系病态造血细胞影响的研究。北京中医药大学学报，1995，18(5)：34
32．黄韬，黄振翘，周永明，等。骨髓增生异常综合征骨髓细胞对不同中药治疗的反应性研究。第三届中国中医血液病学术论文集，上海：上海中医药大学，1999．11
33. Hoppc RT. Secondary leukemia and myelodysplastic syndromes after treatment for Hodgkin's disease. Leuk Res 1992, 6(Suppl): 135
34. Rosenbloom B, Schreck R, Koeffler HP et al. Therapy-related myelodysplastic syndromes. Hematol/oncol Clin Nor Am, 1992, 6(3): 707
35. Levine EG, Blocmfild CD. Leukemia and myelodysplastic syndromes secondary to drug, radiation and environmental exposure. Semin Oncol, 1992; 19:47
36. Yardly-Joners A, Anderson D, Prker DV. The toxicity of benzene and its metabolism and molecular pathology in human risk assessment. Br J Ind Med, 1991, 48:437
37. Brandt L. Exposure to organic solvents and risk of hematological maligancies. Leuk Res, 1992,6(1): 67
38. Nisse C, Lorthois C, Dorp V et al. Exposure to occupational and environmental factors in myelodysplastic Syndromes. Preliminary results of a case-control study. Leuk, 1995, 9:693
39. West RR, Stafford DA, Farrow A et al. Occupational and environmental exposures and.myelodysplasia:A Case-control study. Leuk Res, 1995,19:127
40. Mele A, Szklo M, Visani G et al. Hair dye used and other risk factors for leukemia and preleukemia. A case-control study. Am J Epidemioi, 1994,139:609
41．黄友章，杨平地，汪声恒，等。骨髓增生异常综合征与再生障碍性贫血相互转化观察1例报告。海军总医院学报，2001，14(1)：63～64
42．王冬梅，马茉莉。结核后骨髓增生异常综合征5例临床分析。白血病·淋巴瘤，2001，10(4)：240～241
43. Levine EG, Blocmfild CD. Leukemia and myelodysplastic syndromes secondary to drug, radiation and envionmental exposure. Semin Oncol, 1992 (19): 47
44．胡喜梅，薛文韬，高晖，等。骨髓增生异常骨髓细胞免疫表型的探讨．临床血液学杂志，1998，11(3)：101～104
45．谢彦晖，林果为，竹髓增生异常综合征血细胞酶及同功酶改变的研究进展．中华血液学杂志，1993，14(8)：440～442
46. Sawada K, Sato N, Notoy A, et al. Proliferation and differentiation of myelodysplastic CD_(34)~+cells: phenotypic subpopulations of narrow CD_(34)~+cells. Blood, 1995, 85(1): 194-202
47. Takahiro O, M asaya O, Tohru I, et al. Myclodysplastic syndrome with B cell eionality in a patient five years after renal transplantation. Inte J Hematol, 1998, 68(1): 61～65
48．徐开林，王立，郝玉书，等。骨髓增生异常综合征Evil T和MDS-Evil基因表达的研究．中华血液学杂志，1998，19(6)：315～319
49. Hellstrom LE, Kanter LL, Ost A. Morphological change and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoitin. Leuk Res, 1997, 21(5): 415～425
50. Deliliers gl, Soligo D, OrianiA et al. Increased expression of bcl-2 protein in the bone marrow biopsies of patients with primary MDS. Leuk Res, 1994, 18(suppll):5
51. Davis RE, Greenberg P1. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes (MDS): immuostaining of bone marrow (BM) biopsies. Blood, 1994, 84(suppll): 314a
52．操洲虹，李蓉生，李琦。细胞因子对骨髓增生异常综合征造血细胞凋亡的影响及临床意义。中华血液学杂志，1998，18(1)：27～30
53．邓家栋，杨崇礼，杨天楹，等。临床血液病学。上海：上海科技出版社。753～765
54. Bennet JM et al. Proposals for the classification of myeiodysplastic syndrome. Brit J Haematol, 1982,51:89
55．肖志坚，郝玉书。骨髓增生异常综合征的诊断和治疗。中华血液学杂志。2004，25(1)：61
56. Jackson G, Taylor P, Smith GM, et al. A multicentre, open, non-comparative phase Ⅱ study of a combination of fludarabine phosphate, cytarabine and granulocyte
colony-stimulating factor in relapsed and refractory acute myeloid ieukaemia and de novo refractory anaemia with excess of blasts in transformation. Br J Haematol, 2001, 112:127-137
57. Beran M, Shen Y, Kantarjian H, et al. High-dose chemotherapy in high-risk myelodysplastic syndrome. Cancer, 2001, 92:1999-2015
58. Okamoto T, Kanamaru A, Shimazaki C, et al. Combination chemotherapy with risk factor-adjusled dose attenuation for high-risk myclodysplastic syndrome and resulting leukemia in the multicenter study of the Japan Adult Leukemia Study Group (JALSG): results of an interim analysis. IntJ He matol, 2000, 72:200-205
59. Saito K, Nakamura Y, yoyagi M, et al. Low dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) for previously treated patients with relapsed or primary resistant acute myelogenous leukemia (AML) and previously untreated elderly patients with AML, secondary AML, and refractory anemia with excess blasts in transformation. Int J He matol, 2000, 71:238-244
60. Hast R, Walivik J, Folin A, et al. Long-term follow-up of 18 patients with myelodysplastic syndromes responding to recombinant erythropoietin treatment. Leuk Res, 2001, 25:13-18
61. Molldrem J J, Jiang Y X, M avroudis D, et al. Hematological response of patients with myelodysplastic syndrome (MDS) to antithymocyte globuline (ATG) treatment is assoicated with a loss of CD_8~+T-cell mediated CFU-GM inhibition. Blood, 1997, 90(Suppl): 85a
62. Jonasova A, Neuwirtova R, Cermak J, et al. Cyclosporin A therapy in hypoplastic, myelodysplastic syndrome patients and certain refractory anemia without hypoplastic bone marrow. Brit J Hematol, 1998, 100:304
63. I Raza A, Meyer P, Dutt D, et al . Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood, 2001, 98:958-965
64. Grossl A, Fabbri A, Santini V, et al. Amifostine in the treatment of low risk myelodysplastic syndromes. Haematologica, 2000, 85:367～371
65. Raza A,Qawi H, Lisak L, et al. Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifyiline, and ciprofioxacin with or without dexamethasone. Blood, 2000, 95:1580～1587
66. Tefferi A, Elliott MA, Steensma DP, et al. Amifosline nlone and in combination with erythropoietin fox the treatment of favorable myelodysplastic syndrome. Leuk Res, 2001, 25:183～185
67. Zorat F, Shetty V, Dull D, ea al. The clinical and biological effects of thalidomide with mylodysplastic syndromes. Br J Ilaematol, 2001, 115:881～894
68. Cortelezzi A, Cattaneo C, Sarina B, et al. Efficacy of N-acetylcysteine and all-trans retinoic acid in restoring in vitro effective hemopoiesis in myelodysplastic syndromes. Leuk Res, 2000, 24:129～13
69. Venditti A, Tamburini A, Buccisano F, et al. Aphase-Ⅱ trial of all-trans retinoic acid and low dose cytosine arabinoside for the treatment of high risk myelodysplastic syndromes. Ann Hematol, 2000, 79:138～142
70. Stasi R, Brunetti M, Terzoli E, et al. Sustained response to recombinant human erythropoietin and intermittent all-trans retinoic acid in patients with myelodysplastic syndromes. Blood, 2002, 99:1578～1584
71. Hofmann WK, Kell WJ, Fenaux P, et al. Oral 9-cis retinoic aeid(Alit-retinoin) in the treatment of myelodysplastic syndromes:results from a pilot study Leukemia, 2000, 14:1583～1588
72. M illibovsky L, Diez A, Perez-Vila E, et al. Vitamin D treatment in m yelodysplastic syndromes. Brit J Hematol, 1009,199:516
73. KizakiM, Takayam a N, Kaw asi Y, et a I.Development of acute erythremia from myelodysplastic syndrome after treatment with 1, 25-dihdroxy-vitamin D3 [J]. Amer J Hem atol, 2001, 67:215
74. Teofili L, Martini M,di Mario A, et al. Expression of p15 (INK4b) gene during megakaryocytic differentiation of normal and myelodysplastic hematopoietic progenitors. Blood, 2001, 98:495-497
75. Tien HP, Tang JH, Tsay W, et al. Methylation of the p15 (INK4B) gene in myelodysplastic syndrome: it can be detected early at diagnosis or during disease
progression and is highly associated with leukaemic transformation. Br J Haematol, 2001, 112:148-154
76. Lubbert M, Wijermans P, Kunzmann R, et al. Cytogenetic responses in high-risk myelodysplastic syndromc follwing low dosc trcatment with the DNA methylation inhibitor 5-aza-2-deoxycytidine. Br J Hacmatol, 2001, 114:349-357
77. Takam i A, Asakura H, M akao S Menatetranone, a vilamin K2 analog,ameliorate cytopcnia in patients with refractory anemia of myclodysplastisyndrome[JJAnn Hem atol, 2002, 81:16
78．张琳，杨青，郭建民，等。二氧化二砷治疗高危骨髓增生异常综合征22例．[J]河南医科大学学报，2001，36：772
79．丛秀丽，马永贞，钱林生。临床血液学杂志，2003，16(4)：180～182
80．张之南，沈悌，丁训杰，等。《血液病诊断及疗效标准》，北京：科技出版社，1998：260
81．张洪钧，孙颖立，陈信义，等。中医药治疗骨髓增生异常综合征．北京中医学院学报，1993，16(3)：39～41
82．毕临林。中药治疗骨髓增生异常综合征87例。河南中医。2001，21(2)：42
83．唐由君。中药为主治疗骨髓增生异常综合征22例的观察。浙江中医杂志，1992，(5)：204
84．唐由军，邬佐莉。骨髓增生异常综合征治经验。浙江中医杂志，1995，2：53～54
85. Bogdanovic AD, Jankovic GM, coiovic MD.Aoptosis in bone marrow of myelodysplastic syndrome patients. Blood, 1996, 87:3064
86. Heilstrom-Lindberg E, Kanter Lewensohn L,Ost A. Morphological change and apoptosis in bone marrow from patients with myelodysplastic syndromes treated with granulocyte-CSF and erythropoitin. Leuk Res ,1997, 21:415～425
87. Raza A, Mundle S,Shetty V, et al. Novel insights into the biology of myelodysplastic syndromes:excessive apoptosis and the role of cytokines. Int J He matol, 1996, 63:265-278
88. Kliche KO, Andxeeff M. Hyperapoptosis as pathophysiologic basis of myeiodysplastic syndromes (MDS). Blood, 1996, 88:639
89. Bouscary D, Ves JD, Guesnu M, et al. Fas/Apo-1(CD_(95))expression and apoptosis in
patients with myelodysplastic syndromes Leukemia, 1997, 11:839～845
90. Tsoplou P, Kourakli-Symeonidis A, Thepoulou E, et al.Apoptosis in patients with myelodysplastic syndrome (MDS): differential involvement of marrow cell in early versus advanced cases and correlation with the expression of apoptosis related genes Blood, 1997, 90: 203a
91. Mufti GJ. Ineffective haemapoiesis and apoptosis in myelodysplastic syndromes Br J Haematol, 1998, 101:220～230
92. Rajapaksa R, Ginzlon N, Rote LS, et al Altered oncoprotein expression and apoptosis in myelodysplastic syndrome marrow cells. Blood, 1996, 88:4275～4287